Alcon Loses CEO And Eye Drugs After Dragging On Novartis Financials
This article was originally published in Scrip
Executive Summary
Novartis is set to overhaul its eye care business Alcon after a lackluster 2015, focusing on its core Surgical and Vision Care business by cleaving its ophthalmic pharmaceuticals business and repositioning it into the Pharmaceuticals division.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.